Plaque Psoriasis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for plaque psoriasis. 317 active patents protecting 14 drugs from 8+ originators. First major cliff: 2027. Daily refresh.

14
Approved drugs
317
Active US patents
61/100
Avg vulnerability
$8.1B
Annual revenue covered

Originators in Plaque Psoriasis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Arcutis 68 patents Merck & Co. 42 patents Generic (originally Merck/Upjohn) 29 patents Amgen 23 patents Biogen 18 patents Fougera Pharms 8 patents Bristol-Myers Squibb 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating plaque psoriasis. Each bar = one year. Y-axis scaled to peak year (68 patents).

3
26
7
27
15
28
13
30
40
31
6
32
7
33
44
34
32
35
11
36
68
37
1
38
25
39
28
40
8
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Daliresp
ROFLUMILAST
 Arcutis 68 62 — 2037-06-07
Otezla
APREMILAST
 Amgen 23 41 $2.1B 2028-02-16
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Diprolene
BETAMETHASONE DIPROPIONATE
 Merck & Co. 20 62 — 2027-09-27
Tecfidera
DIMETHYL FUMARATE
 Biogen 18 65 $2.8B 2028-02-07
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Temovate
CLOBETASOL PROPIONATE
 Fougera Pharms 8 50 — 2028-11-05
Sotyktu
DEUCRAVACITINIB
 Bristol-Myers Squibb 4 41 $291M 2033-11-07
Derma-Smoothe/Fs
FLUOCINOLONE ACETONIDE
 Eurofarma 4 72 — 2027-08-12
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13
Topicort
DESOXIMETASONE
 Taro 1 83 — 2028-09-01
Dovonex
CALCIPOTRIENE
 — 1 83 — 2028-05-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9849027 Derma-Smoothe/Fs method of use 88 2028-11-07
7998108 Derma-Smoothe/Fs method of use 83 2028-01-12
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
8460641 Verdeso method of use 80 2027-08-13
8399514 Tecfidera method of use 80 2028-02-07
8399514 Tecfidera method of use 80 2028-02-07
8263580 Dovonex method of use 80 2028-05-07
8277780 Topicort method of use 80 2028-09-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10000480 Sotyktu composition of matter 0 2033-11-07
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 5 2028-02-16
7427638 Otezla composition of matter 13 2028-02-16
10537585 Decadron formulation 25 2037-12-18
9855334 Temovate formulation 25 2035-03-11
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13

Related